Selected research
Industry Growth & Trends
Global Benign Prostatic Hypertrophy Medication Industry Growth and Trends Forecast to 2032
Market perspective
The global Benign Prostatic Hypertrophy Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Benign Prostatic Hypertrophy Medication include Abbott Laboratories, Allergan, Inc, Astellas, Kissei Pharmaceutical, Merck & Co., Sanofi, Hainan Selike Pharmaceutical Co., Ltd., Hunan Shentaichun Pharmaceutical Co., Ltd. and China Resources Saike Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Benign Prostatic Hypertrophy Medication market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Benign Prostatic Hypertrophy Medication market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Benign Prostatic Hypertrophy Medication market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Benign Prostatic Hypertrophy Medication.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Benign Prostatic Hypertrophy Medication market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Benign Prostatic Hypertrophy Medication Market by Company
Abbott Laboratories
Allergan, Inc
Astellas
Kissei Pharmaceutical
Merck & Co.
Sanofi
Hainan Selike Pharmaceutical Co., Ltd.
Hunan Shentaichun Pharmaceutical Co., Ltd.
China Resources Saike Pharmaceutical Co., Ltd.
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Jiangsu Yongan Pharmaceutical Co., Ltd.
Kunming Jida Pharmaceutical Co., Ltd.
Lunan Beite Pharmaceutical Co., Ltd.
Nanjing Meirui Pharmaceutical Co., Ltd.
Shandong Langnuo Pharmaceutical Co., Ltd.
Shanghai Modern Pharmaceutical Co., Ltd.
Shanghai Abbott Pharmaceutical Co., Ltd.
Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
Suzhou Dongrui Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhongshan Kekekang Pharmaceutical Co., Ltd.
Benign Prostatic Hypertrophy Medication Segment by Type
Terazosin
Tamsulosin
Silodosin
Prusatide
Finasteride
Aprilite
Alfuzosin
Benign Prostatic Hypertrophy Medication Segment by Application
Hospital
Clinic
Other
Benign Prostatic Hypertrophy Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hypertrophy Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hypertrophy Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hypertrophy Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hypertrophy Medication manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Benign Prostatic Hypertrophy Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Major Company of Terazosin
Table 2. Major Company of Tamsulosin
Table 3. Major Company of Silodosin
Table 4. Major Company of Prusatide
Table 5. Major Company of Finasteride
Table 6. Major Company of Aprilite
Table 7. Major Company of Alfuzosin
Table 8. Global Benign Prostatic Hypertrophy Medication Sales by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 9. Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 10. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Type (2021-2026)
Table 11. Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (US$ Million)
Table 12. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Type (2021-2026)
Table 13. Global Benign Prostatic Hypertrophy Medication Price by Type (2021-2026) & (US$/Unit)
Table 14. Global Benign Prostatic Hypertrophy Medication Sales by Type (2027-2032) & (K Units)
Table 15. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Type (2027-2032)
Table 16. Global Benign Prostatic Hypertrophy Medication Sales by Type (2027-2032) & (US$ Million)
Table 17. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Type (2027-2032)
Table 18. Global Benign Prostatic Hypertrophy Medication Price by Type (2027-2032) & (US$/Unit)
Table 19. North America Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 20. North America Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (US$ Million)
Table 21. Europe Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 22. Europe Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (US$ Million)
Table 23. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 24. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (US$ Million)
Table 25. Latin America Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 26. Latin America Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (US$ Million)
Table 27. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 28. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (US$ Million)
Table 29. Benign Prostatic Hypertrophy Medication Industry Trends
Table 30. Benign Prostatic Hypertrophy Medication Industry Drivers
Table 31. Benign Prostatic Hypertrophy Medication Industry Opportunities and Challenges
Table 32. Benign Prostatic Hypertrophy Medication Industry Restraints
Table 33. Global Benign Prostatic Hypertrophy Medication Sales Revenue by Company (US$ Million) & (2021-2026)
Table 34. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Company (2021-2026)
Table 35. Global Benign Prostatic Hypertrophy Medication Sales by Company (2021-2026) & (K Units)
Table 36. Global Benign Prostatic Hypertrophy Medication Sales Share by Company (2021-2026)
Table 37. Global Benign Prostatic Hypertrophy Medication Market Price by Company (2021-2026) & (US$/Unit)
Table 38. Global Benign Prostatic Hypertrophy Medication Industry Company Ranking, 2024 VS 2025 VS 2026
Table 39. Global Benign Prostatic Hypertrophy Medication Major Company Production Sites and Headquarters
Table 40. Global Benign Prostatic Hypertrophy Medication Company, Product Type & Application
Table 41. Global Benign Prostatic Hypertrophy Medication Company Establishment Date
Table 42. Global Company Market Concentration Ratio (CR5 and HHI)
Table 43. Global Benign Prostatic Hypertrophy Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 44. Global Benign Prostatic Hypertrophy Medication Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032
Table 45. Global Benign Prostatic Hypertrophy Medication Sales by Region (2021-2026) & (K Units)
Table 46. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Region (2021-2026)
Table 47. Global Benign Prostatic Hypertrophy Medication Sales by Region (2021-2026) & (US$ Million)
Table 48. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Region (2021-2026)
Table 49. Global Benign Prostatic Hypertrophy Medication Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 50. Global Benign Prostatic Hypertrophy Medication Sales by Region (2027-2032) & (K Units)
Table 51. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Region (2027-2032)
Table 52. Global Benign Prostatic Hypertrophy Medication Sales by Region (2027-2032) & (US$ Million)
Table 53. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Region (2027-2032)
Table 54. Global Benign Prostatic Hypertrophy Medication Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032)
Table 55. Global Benign Prostatic Hypertrophy Medication Sales by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 56. Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 57. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Application (2021-2026)
Table 58. Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (US$ Million)
Table 59. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Application (2021-2026)
Table 60. Global Benign Prostatic Hypertrophy Medication Price by Application (2021-2026) & (US$/Unit)
Table 61. Global Benign Prostatic Hypertrophy Medication Sales by Application (2027-2032) & (K Units)
Table 62. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Application (2027-2032)
Table 63. Global Benign Prostatic Hypertrophy Medication Sales by Application (2027-2032) & (US$ Million)
Table 64. Global Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Application (2027-2032)
Table 65. Global Benign Prostatic Hypertrophy Medication Price by Application (2027-2032) & (US$/Unit)
Table 66. North America Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 67. North America Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (US$ Million)
Table 68. Europe Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 69. Europe Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (US$ Million)
Table 70. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 71. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (US$ Million)
Table 72. Latin America Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 73. Latin America Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (US$ Million)
Table 74. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 75. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (US$ Million)
Table 76. Abbott Laboratories Company Information
Table 77. Abbott Laboratories Business Overview
Table 78. Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolio
Table 80. Abbott Laboratories Recent Development
Table 81. Allergan, Inc Company Information
Table 82. Allergan, Inc Business Overview
Table 83. Allergan, Inc Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolio
Table 85. Allergan, Inc Recent Development
Table 86. Astellas Company Information
Table 87. Astellas Business Overview
Table 88. Astellas Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Astellas Benign Prostatic Hypertrophy Medication Product Portfolio
Table 90. Astellas Recent Development
Table 91. Kissei Pharmaceutical Company Information
Table 92. Kissei Pharmaceutical Business Overview
Table 93. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolio
Table 95. Kissei Pharmaceutical Recent Development
Table 96. Merck & Co. Company Information
Table 97. Merck & Co. Business Overview
Table 98. Merck & Co. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 100. Merck & Co. Recent Development
Table 101. Sanofi Company Information
Table 102. Sanofi Business Overview
Table 103. Sanofi Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Sanofi Benign Prostatic Hypertrophy Medication Product Portfolio
Table 105. Sanofi Recent Development
Table 106. Hainan Selike Pharmaceutical Co., Ltd. Company Information
Table 107. Hainan Selike Pharmaceutical Co., Ltd. Business Overview
Table 108. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 110. Hainan Selike Pharmaceutical Co., Ltd. Recent Development
Table 111. Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
Table 112. Hunan Shentaichun Pharmaceutical Co., Ltd. Business Overview
Table 113. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 115. Hunan Shentaichun Pharmaceutical Co., Ltd. Recent Development
Table 116. China Resources Saike Pharmaceutical Co., Ltd. Company Information
Table 117. China Resources Saike Pharmaceutical Co., Ltd. Business Overview
Table 118. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 120. China Resources Saike Pharmaceutical Co., Ltd. Recent Development
Table 121. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
Table 122. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Business Overview
Table 123. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 125. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Recent Development
Table 126. Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
Table 127. Jiangsu Yongan Pharmaceutical Co., Ltd. Business Overview
Table 128. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 130. Jiangsu Yongan Pharmaceutical Co., Ltd. Recent Development
Table 131. Kunming Jida Pharmaceutical Co., Ltd. Company Information
Table 132. Kunming Jida Pharmaceutical Co., Ltd. Business Overview
Table 133. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 135. Kunming Jida Pharmaceutical Co., Ltd. Recent Development
Table 136. Lunan Beite Pharmaceutical Co., Ltd. Company Information
Table 137. Lunan Beite Pharmaceutical Co., Ltd. Business Overview
Table 138. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 140. Lunan Beite Pharmaceutical Co., Ltd. Recent Development
Table 141. Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
Table 142. Nanjing Meirui Pharmaceutical Co., Ltd. Business Overview
Table 143. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 145. Nanjing Meirui Pharmaceutical Co., Ltd. Recent Development
Table 146. Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
Table 147. Shandong Langnuo Pharmaceutical Co., Ltd. Business Overview
Table 148. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 150. Shandong Langnuo Pharmaceutical Co., Ltd. Recent Development
Table 151. Shanghai Modern Pharmaceutical Co., Ltd. Company Information
Table 152. Shanghai Modern Pharmaceutical Co., Ltd. Business Overview
Table 153. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 155. Shanghai Modern Pharmaceutical Co., Ltd. Recent Development
Table 156. Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
Table 157. Shanghai Abbott Pharmaceutical Co., Ltd. Business Overview
Table 158. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 160. Shanghai Abbott Pharmaceutical Co., Ltd. Recent Development
Table 161. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
Table 162. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
Table 163. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 165. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Development
Table 166. Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
Table 167. Suzhou Dongrui Pharmaceutical Co., Ltd. Business Overview
Table 168. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 169. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 170. Suzhou Dongrui Pharmaceutical Co., Ltd. Recent Development
Table 171. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
Table 172. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
Table 173. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 174. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 175. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Development
Table 176. Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
Table 177. Zhongshan Kekekang Pharmaceutical Co., Ltd. Business Overview
Table 178. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 179. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 180. Zhongshan Kekekang Pharmaceutical Co., Ltd. Recent Development
Table 181. North America Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 182. North America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 183. North America Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2026)
Table 184. North America Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032) & (K Units)
Table 185. North America Benign Prostatic Hypertrophy Medication Sales Market Share Forecast by Country (2027-2032)
Table 186. North America Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 187. North America Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026) & (US$ Million)
Table 188. North America Benign Prostatic Hypertrophy Medication Market Share by Country (2021-2026)
Table 189. North America Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 190. North America Benign Prostatic Hypertrophy Medication Market Share Forecast by Country (2027-2032)
Table 191. Europe Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 192. Europe Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 193. Europe Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2026)
Table 194. Europe Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032) & (K Units)
Table 195. Europe Benign Prostatic Hypertrophy Medication Sales Market Share Forecast by Country (2027-2032)
Table 196. Europe Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 197. Europe Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026) & (US$ Million)
Table 198. Europe Benign Prostatic Hypertrophy Medication Market Share by Country (2021-2026)
Table 199. Europe Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 200. Europe Benign Prostatic Hypertrophy Medication Market Share Forecast by Country (2027-2032)
Table 201. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 202. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 203. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2026)
Table 204. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032) & (K Units)
Table 205. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Market Share Forecast by Country (2027-2032)
Table 206. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 207. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026) & (US$ Million)
Table 208. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Share by Country (2021-2026)
Table 209. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 210. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Share Forecast by Country (2027-2032)
Table 211. Latin America Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 212. Latin America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 213. Latin America Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2026)
Table 214. Latin America Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032) & (K Units)
Table 215. Latin America Benign Prostatic Hypertrophy Medication Sales Market Share Forecast by Country (2027-2032)
Table 216. Latin America Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 217. Latin America Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026) & (US$ Million)
Table 218. Latin America Benign Prostatic Hypertrophy Medication Market Share by Country (2021-2026)
Table 219. Latin America Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 220. Latin America Benign Prostatic Hypertrophy Medication Market Share Forecast by Country (2027-2032)
Table 221. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032
Table 222. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 223. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2026)
Table 224. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032) & (K Units)
Table 225. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share Forecast by Country (2027-2032)
Table 226. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 227. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026) & (US$ Million)
Table 228. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Share by Country (2021-2026)
Table 229. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 230. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Share Forecast by Country (2027-2032)
Table 231. Key Raw Materials
Table 232. Raw Materials Key Suppliers
Table 233. Benign Prostatic Hypertrophy Medication Distributors List
Table 234. Benign Prostatic Hypertrophy Medication Customers List
Table 235. Research Programs/Design for This Report
Table 236. Authors List of This Report
Table 237. Secondary Sources
Table 238. Primary Sources
List of Figures
Figure 1. Benign Prostatic Hypertrophy Medication Image
Figure 2. Global Benign Prostatic Hypertrophy Medication Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Benign Prostatic Hypertrophy Medication Market Size (2021-2032) & (US$ Million)
Figure 4. Global Benign Prostatic Hypertrophy Medication Sales (2021-2032) & (K Units)
Figure 5. Terazosin Image
Figure 6. Global Terazosin Sales YoY Growth (2021-2032) & (K Units)
Figure 7. Tamsulosin Image
Figure 8. Global Tamsulosin Sales YoY Growth (2021-2032) & (K Units)
Figure 9. Silodosin Image
Figure 10. Global Silodosin Sales YoY Growth (2021-2032) & (K Units)
Figure 11. Prusatide Image
Figure 12. Global Prusatide Sales YoY Growth (2021-2032) & (K Units)
Figure 13. Finasteride Image
Figure 14. Global Finasteride Sales YoY Growth (2021-2032) & (K Units)
Figure 15. Aprilite Image
Figure 16. Global Aprilite Sales YoY Growth (2021-2032) & (K Units)
Figure 17. Alfuzosin Image
Figure 18. Global Alfuzosin Sales YoY Growth (2021-2032) & (K Units)
Figure 19. Global Benign Prostatic Hypertrophy Medication Market Size Overview by Type (2021-2032) & (US$ Million)
Figure 20. Global Benign Prostatic Hypertrophy Medication Market Share by Type 2025 VS 2032
Figure 21. North America Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Type in 2025
Figure 22. North America Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Type in 2025
Figure 23. Europe Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Type in 2025
Figure 24. Europe Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Type in 2025
Figure 25. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Type in 2025
Figure 26. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Type in 2025
Figure 27. Latin America Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Type in 2025
Figure 28. Latin America Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Type in 2025
Figure 29. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Type in 2025
Figure 30. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Type in 2025
Figure 31. Global Top 5 and 10 Benign Prostatic Hypertrophy Medication Players Market Share by Revenue in 2025
Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 33. Hospital Image
Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (K Units)
Figure 35. Clinic Image
Figure 36. Global Clinic Sales YoY Growth (2021-2032) & (K Units)
Figure 37. Other Image
Figure 38. Global Other Sales YoY Growth (2021-2032) & (K Units)
Figure 39. Global Benign Prostatic Hypertrophy Medication Market Size Overview by Application (2021-2032) & (US$ Million)
Figure 40. Global Benign Prostatic Hypertrophy Medication Market Share by Application 2025 VS 2032
Figure 41. North America Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Application in 2025
Figure 42. North America Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Application in 2025
Figure 43. Europe Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Application in 2025
Figure 44. Europe Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Application in 2025
Figure 45. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Application in 2025
Figure 46. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Application in 2025
Figure 47. Latin America Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Application in 2025
Figure 48. Latin America Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Application in 2025
Figure 49. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share in Volume by Application in 2025
Figure 50. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share in Value by Application in 2025
Figure 51. North America Benign Prostatic Hypertrophy Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 52. North America Benign Prostatic Hypertrophy Medication Sales Share by Country: 2021 VS 2025 VS 2032
Figure 53. North America Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 54. North America Benign Prostatic Hypertrophy Medication Market Share by Country: 2021 VS 2025 VS 2032
Figure 55. Europe Benign Prostatic Hypertrophy Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 56. Europe Benign Prostatic Hypertrophy Medication Sales Share by Country: 2021 VS 2025 VS 2032
Figure 57. Europe Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 58. Europe Benign Prostatic Hypertrophy Medication Market Share by Country: 2021 VS 2025 VS 2032
Figure 59. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 60. Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Share by Country: 2021 VS 2025 VS 2032
Figure 61. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 62. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Share by Country: 2021 VS 2025 VS 2032
Figure 63. Latin America Benign Prostatic Hypertrophy Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 64. Latin America Benign Prostatic Hypertrophy Medication Sales Share by Country: 2021 VS 2025 VS 2032
Figure 65. Latin America Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 66. Latin America Benign Prostatic Hypertrophy Medication Market Share by Country: 2021 VS 2025 VS 2032
Figure 67. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Figure 68. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Share by Country: 2021 VS 2025 VS 2032
Figure 69. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 70. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Share by Country: 2021 VS 2025 VS 2032
Figure 71. Benign Prostatic Hypertrophy Medication Value Chain
Figure 72. Key Raw Materials Price
Figure 73. Manufacturing Cost Structure
Figure 74. Benign Prostatic Hypertrophy Medication Production Mode & Process
Figure 75. Direct Comparison with Distribution Share
Figure 76. Distributors Profiles
Figure 77. Years Considered
Figure 78. Research Process
Figure 79. Key Executives Interviewed
Scope & coverage.
Types
- Terazosin
- Tamsulosin
- Silodosin
- Prusatide
- Finasteride
- Aprilite
- Alfuzosin
Applications
- Hospital
- Clinic
- Other
Companies covered
- Abbott Laboratories
- Allergan, Inc
- Astellas
- Kissei Pharmaceutical
- Merck & Co.
- Sanofi
- Hainan Selike Pharmaceutical Co., Ltd.
- Hunan Shentaichun Pharmaceutical Co., Ltd.
- China Resources Saike Pharmaceutical Co., Ltd.
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- Jiangsu Yongan Pharmaceutical Co., Ltd.
- Kunming Jida Pharmaceutical Co., Ltd.
- Lunan Beite Pharmaceutical Co., Ltd.
- Nanjing Meirui Pharmaceutical Co., Ltd.
- Shandong Langnuo Pharmaceutical Co., Ltd.
- Shanghai Modern Pharmaceutical Co., Ltd.
- Shanghai Abbott Pharmaceutical Co., Ltd.
- Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
- Suzhou Dongrui Pharmaceutical Co., Ltd.
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Zhongshan Kekekang Pharmaceutical Co., Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Benign Prostatic Hypertrophy Medication Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Benign Prostatic Hypertrophy Medication Sales Estimates and Forecasts (2021-2032)
- 1.3 Benign Prostatic Hypertrophy Medication Market by Type
- 1.3.1 Terazosin
- 1.3.2 Tamsulosin
- 1.3.3 Silodosin
- 1.3.4 Prusatide
- 1.3.5 Finasteride
- 1.3.6 Aprilite
- 1.3.7 Alfuzosin
- 1.4 Global Benign Prostatic Hypertrophy Medication Market Size by Type
- 1.4.1 Global Benign Prostatic Hypertrophy Medication Market Size Overview by Type (2021-2032)
- 1.4.2 Global Benign Prostatic Hypertrophy Medication Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Benign Prostatic Hypertrophy Medication Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Benign Prostatic Hypertrophy Medication Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Benign Prostatic Hypertrophy Medication Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Benign Prostatic Hypertrophy Medication Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Benign Prostatic Hypertrophy Medication Industry Trends
- 2.2 Benign Prostatic Hypertrophy Medication Industry Drivers
- 2.3 Benign Prostatic Hypertrophy Medication Industry Opportunities and Challenges
- 2.4 Benign Prostatic Hypertrophy Medication Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Benign Prostatic Hypertrophy Medication Revenue (2021-2026)
- 3.2 Global Top Players by Benign Prostatic Hypertrophy Medication Sales (2021-2026)
- 3.3 Global Top Players by Benign Prostatic Hypertrophy Medication Price (2021-2026)
- 3.4 Global Benign Prostatic Hypertrophy Medication Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Benign Prostatic Hypertrophy Medication Major Company Production Sites & Headquarters
- 3.6 Global Benign Prostatic Hypertrophy Medication Company, Product Type & Application
- 3.7 Global Benign Prostatic Hypertrophy Medication Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Benign Prostatic Hypertrophy Medication Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Benign Prostatic Hypertrophy Medication Players Market Share by Revenue in 2025
- 3.8.3 2025 Benign Prostatic Hypertrophy Medication Tier 1, Tier 2, and Tier 3
4 Benign Prostatic Hypertrophy Medication Regional Status and Outlook
- 4.1 Global Benign Prostatic Hypertrophy Medication Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Benign Prostatic Hypertrophy Medication Historic Market Size by Region
- 4.2.1 Global Benign Prostatic Hypertrophy Medication Sales in Volume by Region (2021-2026)
- 4.2.2 Global Benign Prostatic Hypertrophy Medication Sales in Value by Region (2021-2026)
- 4.2.3 Global Benign Prostatic Hypertrophy Medication Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Benign Prostatic Hypertrophy Medication Forecasted Market Size by Region
- 4.3.1 Global Benign Prostatic Hypertrophy Medication Sales in Volume by Region (2027-2032)
- 4.3.2 Global Benign Prostatic Hypertrophy Medication Sales in Value by Region (2027-2032)
- 4.3.3 Global Benign Prostatic Hypertrophy Medication Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Benign Prostatic Hypertrophy Medication by Application
- 5.1 Benign Prostatic Hypertrophy Medication Market by Application
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Benign Prostatic Hypertrophy Medication Market Size by Application
- 5.2.1 Global Benign Prostatic Hypertrophy Medication Market Size Overview by Application (2021-2032)
- 5.2.2 Global Benign Prostatic Hypertrophy Medication Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Benign Prostatic Hypertrophy Medication Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Benign Prostatic Hypertrophy Medication Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Benign Prostatic Hypertrophy Medication Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Benign Prostatic Hypertrophy Medication Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Abbott Laboratories
- 6.1.1 Abbott Laboratories Company Information
- 6.1.2 Abbott Laboratories Business Overview
- 6.1.3 Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.1.5 Abbott Laboratories Recent Developments
- 6.2 Allergan, Inc
- 6.2.1 Allergan, Inc Company Information
- 6.2.2 Allergan, Inc Business Overview
- 6.2.3 Allergan, Inc Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.2.5 Allergan, Inc Recent Developments
- 6.3 Astellas
- 6.3.1 Astellas Company Information
- 6.3.2 Astellas Business Overview
- 6.3.3 Astellas Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Astellas Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.3.5 Astellas Recent Developments
- 6.4 Kissei Pharmaceutical
- 6.4.1 Kissei Pharmaceutical Company Information
- 6.4.2 Kissei Pharmaceutical Business Overview
- 6.4.3 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.4.5 Kissei Pharmaceutical Recent Developments
- 6.5 Merck & Co.
- 6.5.1 Merck & Co. Company Information
- 6.5.2 Merck & Co. Business Overview
- 6.5.3 Merck & Co. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.5.5 Merck & Co. Recent Developments
- 6.6 Sanofi
- 6.6.1 Sanofi Company Information
- 6.6.2 Sanofi Business Overview
- 6.6.3 Sanofi Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Sanofi Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.6.5 Sanofi Recent Developments
- 6.7 Hainan Selike Pharmaceutical Co., Ltd.
- 6.7.1 Hainan Selike Pharmaceutical Co., Ltd. Company Information
- 6.7.2 Hainan Selike Pharmaceutical Co., Ltd. Business Overview
- 6.7.3 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.7.5 Hainan Selike Pharmaceutical Co., Ltd. Recent Developments
- 6.8 Hunan Shentaichun Pharmaceutical Co., Ltd.
- 6.8.1 Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
- 6.8.2 Hunan Shentaichun Pharmaceutical Co., Ltd. Business Overview
- 6.8.3 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.8.5 Hunan Shentaichun Pharmaceutical Co., Ltd. Recent Developments
- 6.9 China Resources Saike Pharmaceutical Co., Ltd.
- 6.9.1 China Resources Saike Pharmaceutical Co., Ltd. Company Information
- 6.9.2 China Resources Saike Pharmaceutical Co., Ltd. Business Overview
- 6.9.3 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.9.5 China Resources Saike Pharmaceutical Co., Ltd. Recent Developments
- 6.10 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- 6.10.1 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
- 6.10.2 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Business Overview
- 6.10.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.10.5 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Recent Developments
- 6.11 Jiangsu Yongan Pharmaceutical Co., Ltd.
- 6.11.1 Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
- 6.11.2 Jiangsu Yongan Pharmaceutical Co., Ltd. Business Overview
- 6.11.3 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.11.5 Jiangsu Yongan Pharmaceutical Co., Ltd. Recent Developments
- 6.12 Kunming Jida Pharmaceutical Co., Ltd.
- 6.12.1 Kunming Jida Pharmaceutical Co., Ltd. Company Information
- 6.12.2 Kunming Jida Pharmaceutical Co., Ltd. Business Overview
- 6.12.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.12.5 Kunming Jida Pharmaceutical Co., Ltd. Recent Developments
- 6.13 Lunan Beite Pharmaceutical Co., Ltd.
- 6.13.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
- 6.13.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
- 6.13.3 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.13.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
- 6.14 Nanjing Meirui Pharmaceutical Co., Ltd.
- 6.14.1 Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
- 6.14.2 Nanjing Meirui Pharmaceutical Co., Ltd. Business Overview
- 6.14.3 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.14.4 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.14.5 Nanjing Meirui Pharmaceutical Co., Ltd. Recent Developments
- 6.15 Shandong Langnuo Pharmaceutical Co., Ltd.
- 6.15.1 Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
- 6.15.2 Shandong Langnuo Pharmaceutical Co., Ltd. Business Overview
- 6.15.3 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.15.4 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.15.5 Shandong Langnuo Pharmaceutical Co., Ltd. Recent Developments
- 6.16 Shanghai Modern Pharmaceutical Co., Ltd.
- 6.16.1 Shanghai Modern Pharmaceutical Co., Ltd. Company Information
- 6.16.2 Shanghai Modern Pharmaceutical Co., Ltd. Business Overview
- 6.16.3 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.16.4 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.16.5 Shanghai Modern Pharmaceutical Co., Ltd. Recent Developments
- 6.17 Shanghai Abbott Pharmaceutical Co., Ltd.
- 6.17.1 Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
- 6.17.2 Shanghai Abbott Pharmaceutical Co., Ltd. Business Overview
- 6.17.3 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.17.4 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.17.5 Shanghai Abbott Pharmaceutical Co., Ltd. Recent Developments
- 6.18 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
- 6.18.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
- 6.18.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
- 6.18.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.18.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.18.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Developments
- 6.19 Suzhou Dongrui Pharmaceutical Co., Ltd.
- 6.19.1 Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
- 6.19.2 Suzhou Dongrui Pharmaceutical Co., Ltd. Business Overview
- 6.19.3 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.19.4 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.19.5 Suzhou Dongrui Pharmaceutical Co., Ltd. Recent Developments
- 6.20 Zhejiang Huahai Pharmaceutical Co., Ltd.
- 6.20.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
- 6.20.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
- 6.20.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.20.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.20.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
- 6.21 Zhongshan Kekekang Pharmaceutical Co., Ltd.
- 6.21.1 Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
- 6.21.2 Zhongshan Kekekang Pharmaceutical Co., Ltd. Business Overview
- 6.21.3 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 6.21.4 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 6.21.5 Zhongshan Kekekang Pharmaceutical Co., Ltd. Recent Developments
7 North America by Country
- 7.1 North America Benign Prostatic Hypertrophy Medication Sales by Country
- 7.1.1 North America Benign Prostatic Hypertrophy Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026)
- 7.1.3 North America Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032)
- 7.2 North America Benign Prostatic Hypertrophy Medication Market Size by Country
- 7.2.1 North America Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026)
- 7.2.3 North America Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Benign Prostatic Hypertrophy Medication Sales by Country
- 8.1.1 Europe Benign Prostatic Hypertrophy Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026)
- 8.1.3 Europe Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032)
- 8.2 Europe Benign Prostatic Hypertrophy Medication Market Size by Country
- 8.2.1 Europe Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026)
- 8.2.3 Europe Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Country
- 9.1.1 Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size by Country
- 9.2.1 Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Benign Prostatic Hypertrophy Medication Sales by Country
- 10.1.1 South America Benign Prostatic Hypertrophy Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026)
- 10.1.3 South America Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032)
- 10.2 South America Benign Prostatic Hypertrophy Medication Market Size by Country
- 10.2.1 South America Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026)
- 10.2.3 South America Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country
- 11.1.1 Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size by Country
- 11.2.1 Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Benign Prostatic Hypertrophy Medication Value Chain Analysis
- 12.1.1 Benign Prostatic Hypertrophy Medication Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Benign Prostatic Hypertrophy Medication Production Mode & Process
- 12.2 Benign Prostatic Hypertrophy Medication Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Benign Prostatic Hypertrophy Medication Distributors
- 12.2.3 Benign Prostatic Hypertrophy Medication Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,450USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst